Clinical Trial

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Study acronym: PARTHENON
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.
Protocol Amendment History 1 change
notable Trial sites expanded: 13 -> 18 locations 2026-04-21
Trial Details
NCT Number NCT07446855
Lead Sponsor AstraZeneca
Conditions Solid Tumours
Enrollment 180 participants
Start Date 2026-03-17
Primary Completion 2030-03-29 (estimated)
Study Completion 2030-03-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-11